CAR T-Cell Therapy in Multiple Myeloma: Key Considerations for Patient Selection, Transplant, and Applying Recent Data

This online, on-demand virtual symposium brings together renowned experts to discuss the use of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory multiple myeloma (RRMM). CAR T-cell therapy has proven to be an effective therapy for patients with multiply relapsed multiple myeloma (MM), yielding deep and durable responses. In this educational program, these experts discuss updates of clinical trials evaluating CAR T-cell therapies in patients with MM, expert perspectives on the current role of CAR T-cell therapies in MM, and strategies to identify patients eligible for CAR T-cell therapy and mitigate and manage toxicity related to CAR T-cell therapy.

 

This activity is supported by educational grants from Bristol Myers Squibb; Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC; and Legend Biotech USA, Inc.

 

Target Audience

This educational activity is directed toward hematologists, medical oncologists, researchers, and investigators who are interested in the treatment of hematologic malignancies.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:
  • Discuss the mechanistic rationale underlying the role of CAR T cells in the treatment of multiple myeloma (MM)
  • Determine efficacy and safety results from recent trials assessing CAR T-cell therapies in patients with MM
  • Place these results in the context of evolving paradigms in MM management
  • Plan strategies to monitor and mitigate treatment-associated toxicities in patients who receive CAR T-cell therapy
Additional information

Contact

Name: 
Sherry Fisher
Phone Number: 
+1 (414) 805-0689
Email: 
[email protected]
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
04/26/2022
Course expires: 
04/27/2023
Cost:
$0.00
Accreditation Statement:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement:
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

 

This CME activity is co-provided by The Medical College of Wisconsin and PER, Physician Education Resource, LLC.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.